Bio-Techne Reports Strong Q4 Results Ahead of Merck Acquisition
Bio-Techne Corporation (NASDAQ: TECH) has reported its financial results for the fourth quarter ending June 30, 2026. The company's organic revenue increased by 3% to $321.2 million, while full-year organic and reported revenue remained flat at $1.2 billion.
The company's GAAP earnings per share (EPS) increased to $0.35 from $(0.11) one year ago, while adjusted EPS decreased to $0.52 per diluted share compared to $0.53 in the same quarter last year.
Bio-Techne is set to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. The company's President and Chief Executive Officer, Kim Kelderman, stated that Bio-Techne 'ended fiscal 2026 with improved performance and solid execution across the business.'
The acquisition is expected to create opportunities for customers and employees, according to Kelderman.